BionicM completes funding round as Bio Leg enters the U.S. market
BionicM began U.S. sales of its Bio Leg powered prosthetic knee and completed its first U.S. customer deliveries in August 2024.
Evidence notes
- The company completed a $3 million first-close fundraising round in September 2024, bringing total fundraising including grants and other allocations to $12.7 million.
- BionicM said the capital would support U.S. expansion, technology development, and product improvements for its robotic prosthetic platform.
Company overview
BionicM develops Bio Leg, a powered microprocessor knee for transfemoral amputees. The University of Tokyo spin-out combines motorized assistance, onboard sensing and movement control to support standing, walking and stair use. U.S. sales began in 2024, and the company completed its first customer deliveries that August.